Data: 08/08/2026
Total encontrado: 8
1/8US=22 / Câncer
Copur MS, Rose M, Gettinger SN. Miscellaneous chemotherapeutic agents. In: DeVita Jr V, Lawrence TS, Rosenberg AS. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 8ªed. Philadelphia: Lippincott Willians & Wilkins, 2008. p. 490-5.

AGENTES QUIMIOTERAPICOS; BLEOMYCIN; PROCARBAZINE; THALIDOMIDE; LENALIDOMIDE


2/8US=9 / Urologia
Gardner ER, Di Lorenzo G, Figg WD. Thalidomide and analogs. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 215-23. ISBN 978-1-60327-831-7.

TALIDOMIDA; LENALIDOMIDA; ANGIOGENESE; CANCER DE PROSTATA; IMUNOMODULADORES


3/8US=23-D / Câncer
Hsu C, Chen CN, Cheng AL. Treatment of hepatocellular carcinoma with thalidomide: assessment with power doppler ultrasound. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: liver cancer. New York: Springer, 2009. p. 277-86. ISBN 978-1-4020-9803-1.

TRATAMENTO DO CARCINOMA HEPATOCELULAR COM TALIDOMIDA; VASCULARIZACAO DO TUMOR. ULTRASSOM DOPPLER


4/8US=64 / Câncer
Badros A. Thalidomide in patients with relapsed multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 205-27. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

TALIDOMIDA EM PACIENTES MIELOMA MULTIPLO; TALIDOMIDA E MIELOMA


5/8US=64 / Câncer
Buadi FK, Rajkumar SV. Thalidomide: induction therapy. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 229-37. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

TALIDOMIDA; TERAPIA DE INDUCAO; MIELOMA MULTIPLO; CLONAL DE CELULAS ESTAMINAIS


6/8US=8-A / Dermatologia
Tappeiner G, Wolff K. Thalidomide. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2008. p. 2463-9. ISBN 978-0-07-138076-0.

TALIDOMIDA; FARMACOLOGIA; EFEITOS; USO CLINICO; CONTRA-INDICACAO; DOSAGEM; EFEITOS ADVERSOS


7/8Câncer
Rodríguez MRL, Combariza J, Casas CP, Reveiz L, Buendía J, Carvajal AM, Ramírez HB, Cardona AF. First line therapy for patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation: a systematic review and meta-analysis (hemo-oncolgroup study). Applied Cancer Research, São Paulo: Tecmedd, v.32, n.4, p. 122-41, 2012. ISSN 1980-5578.

Disponível em: http://accamargo.phlnet.com.br//applied/ACR2012;32(4)p.122-41.pdf

QUIMIOTERAPIA; META-ANALISES; MIELOMA MULTIPLO; TRANSPLANTE AUTOLOGO


8/8US=8 / Quimioterapia
Richardson P, Mitsiades CS, Hideshima T, Anderson K. Thalidomide and its analogs for the treatment of hematologic malignancies, including multiple myeloma and solid tumors. In: Chabner BA, Longo DL. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. p. 587-604. ISBN 978-0-7817-5628-6.

TALIDOMIDA; MALIGNIDADES HEMATOLOGICAS; TERAPIA; MIELOMA MULTIPLO; TUMORES SOLIDOS; MECANISMOS DE ACAO; FARMACOLOGIA